Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
Status:
Terminated
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients
who have relapsed or refractory Hodgkin's disease.